Cellebrite DI (NASDAQ:CLBT) Sees Unusually-High Trading Volume After Strong Earnings

Key Points

• Cellebrite beat earnings expectations with adjusted EPS of $0.11 versus the $0.05 consensus, while quarterly revenue of $131.14 million slightly missed estimates.
• The company lowered its third-quarter and full-year revenue guidance and reduced its full-year ARR forecast, signaling slower near-term growth despite subscription momentum and a higher adjusted EBITDA target.
• Trading volume rose 18% to 2.48 million shares, while analysts maintained generally positive ratings but cut price targets; Needham set a $12.50 target and D.A. Davidson set $15.00, both with Buy ratings.

Cellebrite DI Ltd. (NASDAQ:CLBT - Get Free Report) saw strong trading volume on Friday following a stronger than expected earnings report. 2,477,515 shares changed hands during trading, an increase of 18% from the previous session's volume of 2,105,604 shares.The stock last traded at $10.9190 and had previously closed at $10.80.

The company reported $0.11 earnings per share for the quarter, topping the consensus estimate of $0.05 by $0.06. The business had revenue of $131.14 million during the quarter, compared to the consensus estimate of $131.87 million. Cellebrite DI had a net margin of 14.48% and a return on equity of 18.38%.

Trending Headlines about Cellebrite DI

Here are the key news stories impacting Cellebrite DI this week:

• Positive Sentiment: Cellebrite reported adjusted second-quarter EPS of $0.11, above the $0.05 consensus estimate cited by MarketBeat. Subscription revenue continued to grow, and management raised its adjusted EBITDA target. Cellebrite earnings and outlook announcement
• Positive Sentiment: Needham lowered its price target from $15.00 to $12.50 but maintained a Buy rating, implying potential upside from the current trading level. D.A. Davidson also retained its Buy rating. Needham analyst action
• Positive Sentiment: Unusually heavy call-option activity—nearly 20,000 contracts versus average volume of about 586—indicated that some traders were positioning for a rebound, although this is speculative and not a fundamental improvement.
• Neutral Sentiment: Cellebrite completed a planned CEO transition, appointing Shiven Ramji to succeed Thomas E. Hogan. The change could support a strategic reset, but it also introduces uncertainty during a period of lowered forecasts. CEO transition announcement
• Negative Sentiment: The key reason for the selloff was the reduced outlook. Third-quarter revenue guidance of $145 million to $148 million was below the $150.3 million consensus, while full-year revenue guidance of $555 million to $561 million trailed the $568.1 million estimate. Cellebrite also lowered its full-year ARR forecast, signaling slower near-term growth. Cellebrite outlook report
• Negative Sentiment: Quarterly revenue of $131.14 million slightly missed the $131.87 million estimate. Some data providers also characterized EPS of $0.11 as below a $0.12 consensus, reinforcing concerns that the earnings beat was less important than the revenue and ARR shortfalls.
• Negative Sentiment: Multiple law firms announced investigations into possible securities-law violations and whether prior projections and disclosures were accurate. These are allegations, not established findings, but they add legal and reputational risk. Cellebrite investigation notice
• Negative Sentiment: Former CEO Thomas Hogan sold 139,713 shares worth approximately $2.15 million, reducing his position by about 15%. The sale may be unrelated to business conditions, but its timing can weigh on investor sentiment. SEC insider sale filing

Analysts Set New Price Targets

CLBT has been the topic of a number of research analyst reports. Needham & Company LLC lowered their price objective on shares of Cellebrite DI from $15.00 to $12.50 and set a "buy" rating on the stock in a research note on Friday. Weiss Ratings raised Cellebrite DI from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Monday, May 18th. Finally, DA Davidson lowered their price target on Cellebrite DI from $22.00 to $15.00 and set a "buy" rating on the stock in a research report on Friday. Five research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $19.90.

Insider Activity

In other news, CEO Thomas E. Hogan sold 139,713 shares of the company's stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $15.39, for a total transaction of $2,150,183.07. Following the completion of the sale, the chief executive officer directly owned 790,548 shares of the company's stock, valued at $12,166,533.72. This represents a 15.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO David Barter sold 41,734 shares of Cellebrite DI stock in a transaction dated Wednesday, July 8th. The stock was sold at an average price of $16.38, for a total value of $683,602.92. Following the completion of the transaction, the chief financial officer directly owned 334,219 shares in the company, valued at $5,474,507.22. This represents a 11.10% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 297,934 shares of company stock valued at $4,631,972 over the last three months. Insiders own 5.70% of the company's stock.

Institutional Investors Weigh In On Cellebrite DI

Large investors have recently made changes to their positions in the company. Towarzystwo Funduszy Inwestycyjnych PZU SA lifted its position in shares of Cellebrite DI by 81.0% in the 4th quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 1,900 shares of the company's stock valued at $34,000 after acquiring an additional 850 shares in the last quarter. Advisory Services Network LLC purchased a new position in Cellebrite DI during the 3rd quarter worth approximately $40,000. CWM LLC raised its stake in Cellebrite DI by 57.0% during the 4th quarter. CWM LLC now owns 2,449 shares of the company's stock valued at $44,000 after purchasing an additional 889 shares during the period. Elevation Wealth Partners LLC purchased a new stake in shares of Cellebrite DI in the second quarter valued at $44,000. Finally, First Horizon Corp lifted its holdings in shares of Cellebrite DI by 421.8% in the fourth quarter. First Horizon Corp now owns 2,891 shares of the company's stock valued at $52,000 after purchasing an additional 2,337 shares in the last quarter. Institutional investors and hedge funds own 45.88% of the company's stock.

Cellebrite DI Stock Up 1.9%

The firm has a market cap of $2.74 billion, a price-to-earnings ratio of 39.30, a PEG ratio of 1.89 and a beta of 1.18. The company has a 50-day moving average price of $14.52 and a 200 day moving average price of $14.05.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company's technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company's flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source